Swiss medical weekly · 2004
Delayed-onset and long-lasting severe neutropenia due to rituximab.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hofer Silvia, Viollier Romaine, Ludwig Christian
Аннотация
BACKGROUND: Rituximab, a monoclonal antibody, is effective in CD20-positive B-cell lymphoma and is now widely used either as a single agent or in combination with chemotherapy. The antibody's toxicity is generally mild and transient. There are reports of protracted neutropenia in patients treated with rituximab.
CASE REPORT: We report on a patient with Burkitt's lymphoma treated with the hyper-CVAD chemotherapy regimen combined with rituximab. Four weeks after the five months' treatment marked neutropenia and hypogammaglobulinaemia occurred and persisted for one year. Both laboratory findings were not associated with severe infections in our patient.
CONCLUSIONS: Delayed-onset neutropenia is a newly recognised toxicity of rituximab treatment which may last up to one year and be complicated by serious infections.
CASE REPORT: We report on a patient with Burkitt's lymphoma treated with the hyper-CVAD chemotherapy regimen combined with rituximab. Four weeks after the five months' treatment marked neutropenia and hypogammaglobulinaemia occurred and persisted for one year. Both laboratory findings were not associated with severe infections in our patient.
CONCLUSIONS: Delayed-onset neutropenia is a newly recognised toxicity of rituximab treatment which may last up to one year and be complicated by serious infections.